Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Jones

Showing results (211-220 of 215) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 215 results.
Annals of Surgery|January 8, 2025
Remote Symptom Monitoring in Thoracic Surgery Patients After DischargeMarisa Sewell, Thomas Boerner, Caitlin Harrington, et al.
Cancer Research|October 3, 2003
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical modelsBruce Ruggeri, Jasbir Singh, Diane Gingrich, et al.
Molecular Cancer Therapeutics|February 10, 2012
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityJoyce James, Bruce Ruggeri, Robert C Armstrong, et al.
Blood|December 7, 2007
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibRoberto Piva, Bruce Ruggeri, Michael Williams, et al.
Journal of Medicinal Chemistry|December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600EMartin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Pageof 22

Showing results (211-220 of 215) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 215 results.
Annals of Surgery|January 8, 2025
Remote Symptom Monitoring in Thoracic Surgery Patients After DischargeMarisa Sewell, Thomas Boerner, Caitlin Harrington, et al.
Cancer Research|October 3, 2003
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical modelsBruce Ruggeri, Jasbir Singh, Diane Gingrich, et al.
Molecular Cancer Therapeutics|February 10, 2012
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityJoyce James, Bruce Ruggeri, Robert C Armstrong, et al.
Blood|December 7, 2007
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibRoberto Piva, Bruce Ruggeri, Michael Williams, et al.
Journal of Medicinal Chemistry|December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600EMartin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Pageof 22